Industry News
Biotechnology Industry News
Eikon Therapeutics snares $500M series B, pinning constellation of biotech stars to its upper ranks
Eikon Therapeutics snares $500M series B, pinning constellation of biotech stars to its upper ranks fkansteiner Wed, 01/05/2022 - 15:18
Eli Lilly taps Entos’ delivery tech in $50M-plus nucleic acid pact
Eli Lilly taps Entos' delivery tech in $50M-plus nucleic acid pact fkansteiner Wed, 01/05/2022 - 13:31
Annexon shares dip 30% as patient dropouts dog midphase Huntington’s trial
Annexon shares dip 30% as patient dropouts dog midphase Huntington's trial aarmstrong Wed, 01/05/2022 - 12:52
Ultragenyx granted go-ahead to up doses for Angelman antisense therapy that stalled after safety issues
Ultragenyx granted go-ahead to up doses for Angelman antisense therapy that stalled after safety issues aarmstrong Wed, 01/05/2022 - 11:15
VCs plow $115M into next-gen genetic medicine startup SalioGen, teeing up work on eye and liver diseases
VCs plow $115M into next-gen genetic medicine startup SalioGen, teeing up work on eye and liver diseases ntaylor Wed, 01/05/2022 - 06:05
Intellia bags option on autoimmune CAR-T prospect, handing Kyverna rights to use CRISPR tech to create off-the-shelf cell therapy
Intellia bags option on autoimmune CAR-T prospect, handing Kyverna rights to use CRISPR tech to create off-the-shelf cell therapy ntaylor Wed, 01/05/2022 - 05:56
Exelixis nabs Merck veteran as chief medical officer on quest to expand its R&D footprint
Exelixis nabs Merck veteran as chief medical officer on quest to expand its R&D footprint chale Tue, 01/04/2022 - 09:04
Transatlantic VC veterans tap Novo Holdings to raise $124M rare disease fund
Transatlantic VC veterans tap Novo Holdings to raise $124M rare disease fund ntaylor Tue, 01/04/2022 - 05:41
With $415M on the line, Genmab taps Synaffix for antibody-drug conjugate technologies
With $415M on the line, Genmab taps Synaffix for antibody-drug conjugate technologies ntaylor Mon, 01/03/2022 - 10:01
AstraZeneca taps Ionis to join crowd of companies gunning for rare heart disease in deal worth billions in biobucks
AstraZeneca taps Ionis to join crowd of companies gunning for rare heart disease in deal worth billions in biobucks aarmstrong Wed, 12/29/2021 - 10:08
Biogen-Eisai’s potential Aduhelm sequel drug granted speedy review by FDA
Biogen-Eisai's potential Aduhelm sequel drug granted speedy review by FDA aarmstrong Mon, 12/27/2021 - 10:56
Editor’s Corner: Fierce Biotech’s top 10 most read stories in 2021
Editor's Corner: Fierce Biotech's top 10 most read stories in 2021 aarmstrong Wed, 12/22/2021 - 09:04
Novartis inks $800M upfront buyout of Gyroscope to continue eye disease gene therapy M&A spree
Novartis inks $800M upfront buyout of Gyroscope to continue eye disease gene therapy M&A spree ntaylor Wed, 12/22/2021 - 03:29
Aiming to make 70 the new 50, Korify rolls out $100M longevity and mental health venture fund
Aiming to make 70 the new 50, Korify rolls out $100M longevity and mental health venture fund ntaylor Wed, 12/22/2021 - 01:50
PhaseBio blames COVID-19 disruption as cardiovascular study axed
PhaseBio blames COVID-19 disruption as cardiovascular study axed aarmstrong Tue, 12/21/2021 - 09:20
Pfizer reports patient death in early-stage Duchenne gene therapy trial, halts enrollment
Pfizer reports patient death in early-stage Duchenne gene therapy trial, halts enrollment aarmstrong Tue, 12/21/2021 - 08:39
Abandoned by Amgen, Cytokinetics lands deal for Chinese rights to heart failure prospect
Abandoned by Amgen, Cytokinetics lands deal for Chinese rights to heart failure prospect ntaylor Tue, 12/21/2021 - 07:51
Abandoned by Amgen, Cytokinetics lands $50M upfront deal for Chinese rights to heart failure prospect
Abandoned by Amgen, Cytokinetics lands $50M upfront deal for Chinese rights to heart failure prospect ntaylor Tue, 12/21/2021 - 07:51
Sanofi gambles $1B upfront on preclinical oncology biotech, bagging Amunix for its pipeline of T-cell engagers
Sanofi gambles $1B upfront on preclinical oncology biotech, bagging Amunix for its pipeline of T-cell engagers ntaylor Tue, 12/21/2021 - 07:17
Chutes & Ladders—CRISPR Therapeutics bids adieu to R&D head in securities filing
Chutes & Ladders—CRISPR Therapeutics bids adieu to R&D head in securities filing fkansteiner Tue, 12/21/2021 - 07:03